Home Other Navigation Pharmacy + Providers Pharmacy Credentialing Important information Updated Insurance Coverage Information To submit a renewal, submit your updated certificate of insurance to...

Effective Date: July 1, 2026 Introduction, scope, and purpose: Prime Therapeutics LLC and all of its operating units and subsidiaries (“Prime,” “we,” “our”) understands that the privacy of your...

Prime Therapeutics experts share insights about the classification, cost and impact of these revolutionary drugs

These new solutions reflect Prime's distinctive conflict-free approach to the prescription drug supply chain model.

Home Newsroom Custom Content Publications High Cost Therapy Profile 2024-2025 High-Cost Therapy Profile: September 2024 Oncology/ cellular therapy Obecabtagene autoleucel Intravenous (IV) Autolus...

Pharmacy Friends In the latest episode of the “Pharmacy Friends” podcast, learn the latest insights on legislative trends, cutting-edge drug therapies and more from the 22nd annual event Alex Cook...

A female-presenting person speaks at a legislative building, wearing a green blazer and glasses. George Van Antwerp breaks down how Prime is poised to drive affordability in drug pricing Alex Cook...

Upgrade provides streamlined patient support and enhanced digital engagement for data-driven, holistic care

New Biosimilars First Generic Drug Launches Oct. 25, 2024 - sulopenem etzadroxil and probenecid (Orlynvah) The FDA has approved Iterum’s Orlynvah for the treatment of uncomplicated urinary tract...

Read Part 1 – Payer Survey Dive into Part 1 Hear from Prime’s medical pharmacy experts as they dive into the history of the report and offer their insights. Check out the events below to stay...

FDA approved BiTEs: Brand name Generic name Route Target Indication First FDA indication approval date Blincyto Blinatumomab IV anti-CD19 / anti-CD3 Acute lymphocytic leukemia 12/3/2014 Columvi...

Based on the clinical trial, there are certain expectations for how long patients can anticipate seeing the benefits of treatment. The median duration of response was 11.6 months (95% CI, 4.4 to...

This decision to remove REMS comes one year after the FDA loosened REMS requirements and removed the site mandate for CAR T educational and training materials because they deemed the product label...

Scientists have made remarkable progress in understanding the thousands of genes inside our cells and the link they may have to cancer. Researchers continue to discover patient-specific...

Cover image for Prime Therapeutics prioritizes patient-centered care, stays ahead of oncology trends Prime simplifies the cancer care pathway through innovative solutions that help manage complex...

Check out the full conversation on YouTube and dive into the data behind the implementation. “By the time we went live, we only had two minor, minor updates that had to happen. They both happened...

Successfully complete new hire orientation Complete training to gain competency in SA, RxClaims and MSA Toolbox Attend Prime intern activities, such as volunteer opportunities and intern lunch and...

Therapy options Keytruda (Pembrolizumab) Adstiladrin (nadofaragene firadenovec-vncg) Anktiva (nogapendekin alfa inbakicept-pmln) + BCG Study KEYNOTE-057, phase 2, open label; 5-year follow-up;...

References National Cancer Institute. (2020, October 26). Radiopharmaceuticals: radiation therapy enters the molecular age....

Effective: January 2021 Terms of use IF YOU ARE EXPERIENCING A MEDICAL EMERGENCY, DIAL 911 AND/OR SEEK IMMEDIATE ATTENTION FROM A HEALTH CARE PROVIDER. THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE....

Medication insights: teprotumumab-trbw (Tepezza) The U.S. Food and Drug Administration (FDA) first approved teprotumumab-trbw (Tepezza) in January 2020 for the treatment of thyroid eye disease...

Managed Markets Insight & Technology (MMIT)

Sept. 27, 2024 - ustekinumab-aauz (Otulfi) Fresenius Kabi has received FDA approval for Otulfi as a biosimilar to ustekinumab (Stelara). This human interleukin (IL)-12 and IL-23 antagonist is...

Zabrina Watkins Radical welcomeness “At Prime we’re committed to creating an open, inclusive culture that’s purpose-oriented and focused on providing meaningful work for our employees. To do this,...

Oncology Insights On May 16, the U.S. Food and Drug Administration (FDA) granted accelerated approval to intravenous Imdelltra™ (tarlatamab) for the treatment of adults with relapsed/refractory...

March 7, 2025 – rivaroxaban 2.5 mg tablet (Xarelto) Lupin launched a generic to Janssen’s Xarelto Factor Xa inhibitor indicated (1) to reduce the risk of major cardiovascular events in patients...

Tennessee In accordance with Texas Senate Bill 1236, Prime Therapeutics provides Texas-based pharmacies with secure online access to their pharmacy benefit network contracts that were executed on...

Event features Prime's Health Outcomes team

Forbes

Commercial formularies PrimeChoice Accord™ Formulary PrimeChoice Accord™ Formulary Updates NetResults™ A-Series Prescription Drug Guide NetResults™ Balanced Drug Guide NetResults™ F-Series...

New or expanded indications March 12, 2025 – fluocinolone acetonide intravitreal implant (Iluvien) Alimera; corticosteroid; supplemental NDA (sNDA) approved for consolidation of labeling of...

This form is specifically used to request a check reissue. For remittance requests, please use the following link: Pharmacy remittance request - Prime Therapeutics LLC. Prime Therapeutics cannot...

Disclaimer THIS WEBSITE IS AN OPTIONAL RESOURCE FOR HEALTH CARE PROVIDERS ONLY. IF YOU ARE NOT A HEALTH CARE PROVIDER OR AUTHORIZED PROFESSIONAL USER, YOU ARE NOT TO USE THIS SITE AT ALL AND ARE...

New approach aligns with long-standing biosimilar strategy

Category Migration Site ID Liferay Token Category Type Old Categories New Read Category Prime Article Type Dry Run - preview only, do not update content Migration UpdateType Migration Output Log

December 2024 December 2023 December 2021 Pharmacy newsletter from Prime Therapeutics that provides information and updates about Prime services. June 2022 Home Other Navigation Pharmacy +...

publications Fall 2024 Prime Therapeutics Report October 21, 2024 Debuting a new name and design, the 41st edition of our managed care report still offers the same in-depth industry articles on...

cover image for 2026 Medical Pharmacy Trend Report: Part 1 - Payer Survey Packed with insights on real-world management trends for the hottest industry topics Prime Therapeutics...

publications Summer 2024 Prime Therapeutics Report June 11, 2024 The Prime Therapeutics Report is your source for innovative managed care strategies, trends and updates. This issue’s cover story...

July 17, 2026 publications 2026 Medical Pharmacy Trend Report: Part 2 – Drug Overview The 2026 Medical Pharmacy Trend Report: Part 2 – Drug Overview reflects Prime Therapeutics’ long‑standing...

Reimagining pharmacy for our loved ones Please enter a valid video URL. The URL can point to any video file or a Youtube video. View playlist Please enter a valid video URL. The URL can point to...

Expert Clinical Insights Metastatic Melanoma MEDICATION INSIGHTS: Lifileucel (Amtagvi™) The U.S. Food and Drug Administration (FDA) approved lifileucel (Amtagvi™) in February 2024 through the...

Abby Kim, PharmD, BCOP, is a senior director, clinical strategy and oncology specialty solutions, shares key takeaways from the American Journal of Managed Care (AJMC) forum, “Bridging evidence and...

image from Healthcare Advocate Summit Prerak Parikh represented Prime on a panel at Healthcare Advocate Summit 2025 in Las Vegas on Sept. 4 with other payer/PBM professionals Prime Therapeutics At...

Annual conference features presentations, panels, discussions and networking

The American Journal of Managed Care (AJMC): At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection,...

Second annual report gives a transparent overview of Prime’s organizational makeup, highlights milestones along its journey

cover image for MPTR blog Prime expert shares exciting enhancement to Medical Pharmacy Trend Report Lisa Polakowski Lisa Polakowski, PharmD, is the Medical Pharmacy Trend Report director for Prime...

Latest edition of Prime Therapeutics Report spotlights seismic shift in how best to diagnose and manage transthyretin amyloid cardiomyopathy (ATTR-CM) and what it means for patients, providers and...

AAVRh74var adeno-associated virus serotype Rh74var ABSSSI acute bacterial skin and skin structure infections AChR acetylcholine receptor ADHD attention deficit hyperactivity disorder ALK anaplastic...

New indications for approved traditional drugs - 2025 Generic name Brand name Manufacturer Indication(s) Route of administration Month approved* zopapogene imadenovec-drba Papzimeos Precigen...

New indications for approved traditional drugs - 2025 Generic name Brand name Manufacturer Indication(s) Route of administration Month approved* mitomycin intravesical solution Zusduri Urogen...

Generic name Brand name Manufacturer Indication(s) Route of administration Month approved* cosibelimab-ipdl Unloxcyt Checkpoint Metastatic or locally advanced cutaneous squamous cell carcinoma IV...

Jan-Apr 2025 (last posted March 24, 2026): — NADAC Public Report Document #1 — NADAC Public Report Document #2 May-Aug 2025 (last posted January 16, 2026): — NADAC Public Report Document #1 — NADAC...

Learn how Prime champions cancer care through its industry-leading solutions, clinical insights, charitable giving and volunteer efforts

Generic name Brand name Manufacturer Indication(s) Route of administration Month approved* diazoxide choline Vykat XR Soleno Hyperphagia in Prader-Willi syndrome (≥ 4 years of age) Oral March...

publications Quarterly Drug Approvals: October 2024 This report provides an overview of new drugs and indications approved in 2024 Generic Name Brand Name Manufacturer Indication(s) Month Approved*...

Configure the table properties Cellular and gene therapy and biosimilar approvals Oncology drug approvals - 2026 None Configure the table properties Specialty drug approvals Traditional drug...

Adverse reactions or quality problems experienced with the use of these products may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax....

9 Comprehensive outcomes reporting Insert Link Learn more about cystic fibrosis We support members navigating their cystic fibrosis (CF) with a holistic, customized approach to care. Tab 1 Holistic...